Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro

Anti-Cancer Drugs

Volumn 8, Issue 7, 1997, Pages 671-676

  Stahl, Michael ^a   Kasimir Bauer, Sabine ^a   Harstrick, Andreas ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Camptothecin; Etoposide; In vitro studies; Isobologram analysis; Topoisomerase inhibitors

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; PACLITAXEL; VINCRISTINE;

ARTICLE; CELL CYCLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LUNG CANCER; MULTIDRUG RESISTANCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER;

CAMPTOTHECIN; CELL CYCLE; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DRUG INTERACTIONS; ETOPOSIDE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; LUNG NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; POLYMERASE CHAIN REACTION; RHODAMINES; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0030773461     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199708000-00005     Document Type: Article

References (25)

1. Beck WT, Danks MK, Wolverton JS. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv Pharmacol 1994; 29B: 145-69.
2. Chen AY and Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994; 34: 191-218.
3. Wang JC. DNA topoisomerases. Annu Rev Biochem 1995; 54: 665-72.
4. Heck MM, Mittelman WN, Earnshaw WC. Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle, Proc Natl Acad Sci USA 1988; 85: 1086-90.
5. Kambe M, Wakui A, Nakao I, et al. A late phase II study of irinotecan in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1993; 12: 198.
6. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10: 1225-9.
7. Bonomi P. Non-small cell lung cancer chemotherapy. In: Pass III. Mitchell JB. Johnson DH, Turisi AT, eds. Lung cancer: principles and practice. Philadelphia: Lippincott-Raven 1996; 811-23.
8. Beck WT. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerascs in drug action and resistance. J Natl Cancer Inst 1989; 81: 1683-5.
9. Friche E, Danks MK, Schmidt CA, Beck WT. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res 1991; 51: 4213-8.
10. Eng WK, McCabe FL, Tan KB, et al. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 1990; 38: 471-80.
11. Danks MK, Schmidt CA, Cirtain MC, et al. Altered catalyticactivity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM- 26. Biochemistry 1988; 27: 8861-9.
12. Kapoor R, Slade DL, Fujimori A, Pommier Y, Harker W. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol Res 1995; 7: 83-95.
13. Hsiung Y, Jannatipour M, Rose A, et al. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to antitopoisomerase II agents. Cancer Res 1996, 56: 91-9.
14. Tan KB, Mattern MR, Eng WK. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 1989; 81: 1732-6.
15. Sugimoto Y, Tsukahara S, Oh-hara T, et al. Decreased expression of DNA topoisomerase I in camptothecin- resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 1990; 50: 6925-30.
16. Beidler DR, Chang JY, Zhou B, Cheng Y. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin- resistant KB cell lines. Cancer Res 1996; 56: 345-53.
17. cdc2/cyclin H. Cancer Res 1992; 52: 1823-9.
18. Harstrick A, Bokemeyer C, Scharnofske M, et al. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. Cancer Chemother Pharmacol 1993; 33: 43-7.
19. Skehan P, Storeng R, Scudiero D. New colorimetric cytotoxicity assay for anticancer drug screening J Natl Cancer Inst 1990; 82: 1107-12.
20. Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41: 93-140.
21. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDRI (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 7160-4.
22. Chabner BA, Collins JM. Plant alkaloids. In: Cancer chemotheraphy principles and practice Philadelphia: Lippincott 1992; 253-69.
23. Kaufmann SH. Antagonsim between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 1991; 51: 1129-36.
24. Houghton JA, Cheshire PJ, Hallman JD, et al. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin Cancer Res 1996; 2: 107-18.
25. Karato A, Sasaki Y, Shinkai T, et al. Phase I study of CPT-11 and etoposide in patients with refractor; solid tumors. J Clin Oncol 1993; 11: 2030-5.